Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.42 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.42 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60874 | 0.83 | ALDH1A1 (0.61) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL31378891 | 0.81 | IKBKB (0.59) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL2099350 | 0.81 | IKBKB (0.69) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL4837648 | 0.81 | IKBKB (0.59) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL2975427 | 0.81 | KDM4E (0.56) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL25359333 | 0.80 | IKBKB (0.53) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL2874550 | 0.80 | IKBKB (0.53) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL243748 | 0.80 | ALDH1A1 (0.50) | IKBKBALDH1A1KDM4EGAAHPGD | |
| Lithium Ion SCHEMBL2146458 | 0.80 | ALDH1A1 (0.50) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL16992688 | 0.80 | IKBKB (0.53) | IKBKBALDH1A1KDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008135639-A2 | NOVEL USEFUL INHIBITORS | JAAKKOLA PANU (FI) | 2008-11-13 | — | — | WO | claimed |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180271851-A1 | ASSAYS, METHODS AND MEANS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| US-20180271850-A1 | ASSAYS, METHODS AND MEANS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| WO-2008135639-A2 | NOVEL USEFUL INHIBITORS | JAAKKOLA PANU (FI) | 2008-11-13 | — | — | WO | disclosed |
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO | 2008-09-04 | — | — | US | disclosed |
| WO-2006084210-A9 | HIF MODULATING COMPOUNDS AND METHODS OF USE THEREOF | UNIV CALIFORNIA SAN DIEGO (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006084210-A2 | HIF MODULATING COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20040146964-A1 | hydroxylases which act on hypoxia inducible factor alpha (HIF- alpha ) and which are involved in the regulation of the cellular turnover of HIF | ISIS INNOVATION LIMITED (GB) | 2004-07-29 | — | — | US | disclosed |
| EP-1379630-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LIMITED (GB) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002074981-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LTD. (GB) | 2002-09-26 | — | — | WO | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
| US-5593943-A | Heteroaromatically condensed hydroxypyridonecarboxamides, their preparation and use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5378679-A | PRE-AND POSTEMERGENCE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1995-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271851-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | IKBKB 1377/4885ALDH1A1 823/4885KDM4E 239/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | IKBKB 1057/4885ALDH1A1 1204/4885KDM4E 141/4885 |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | PCNA, POLI, VIP | IKBKB 1881/4885ALDH1A1 3388/4885KDM4E 4594/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | IKBKB 1027/4885ALDH1A1 1575/4885KDM4E 139/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | IKBKB 986/4885ALDH1A1 1125/4885KDM4E 233/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | IKBKB 1061/4885ALDH1A1 1611/4885KDM4E 141/4885 |
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | HIF1A, HIF1AN, EGLN3 | IKBKB 232/4885ALDH1A1 744/4885KDM4E 951/4885 |
| US-20180271850-A1 | ASSAYS, METHODS AND MEANS | EGLN3, EGLN2, P4HA1 | IKBKB 1377/4885ALDH1A1 823/4885KDM4E 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.